Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Sierra Oncology, Inc. (SRRA)

54.91   -0.04 (-0.07%) 06-26 23:03
Open: 55.1 Pre. Close: 54.95
High: 55.19 Low: 54.7
Volume: 2,379,048 Market Cap: 1,341(M)
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 55.27 - 55.55 55.55 - 55.78
Low: 54.05 - 54.35 54.35 - 54.59
Close: 54.47 - 54.94 54.94 - 55.32

Technical analysis

as of: 2022-06-24 4:43:24 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 64.46     One year: 75.29
Support: Support1: 54.81    Support2: 54.58
Resistance: Resistance1: 55.18    Resistance2: 64.46
Pivot: 54.9
Moving Average: MA(5): 54.92     MA(20): 54.88
MA(100): 44.28     MA(250): 30.46
MACD: MACD(12,26): 0.4     Signal(9): 0.5
Stochastic oscillator: %K(14,3): 42.2     %D(3): 46.7
RSI: RSI(14): 75.7
52-week: High: 55.18  Low: 14.9
Average Vol(K): 3-Month: 624 (K)  10-Days: 452 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ SRRA ] has closed below upper band by 42.7%. Bollinger Bands are 98.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Sat, 25 Jun 2022
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates BKI, SAIL, SRRA, ATRS - GuruFocus.com

Tue, 21 Jun 2022
Is Sierra Oncology Inc (SRRA) Stock a Bad Value Tuesday? - InvestorsObserver

Fri, 17 Jun 2022
Sierra Oncology (SRRA) Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration - StreetInsider.com

Wed, 15 Jun 2022
Sierra Oncology (NASDAQ:SRRA) Reaches New 1-Year High at $56.62 - Defense World

Tue, 14 Jun 2022
Toronto Financial District Returning to Life With Covid Easing - Yahoo Finance

Wed, 01 Jun 2022
Pfizer Changes Its Mind, Will Sell Down Stake in GSK's Haleon Unit - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 15 (M)
Shares Float 10 (M)
% Held by Insiders 8.5 (%)
% Held by Institutions 63 (%)
Shares Short 1,010 (K)
Shares Short P.Month 1,470 (K)

Stock Financials

EPS -7.16
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.55
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -54.6
Return on Equity (ttm) -97.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) -3.99
Sales Per Share 0
EBITDA (p.s.) -6.27
Qtrly Earnings Growth 0
Operating Cash Flow -79 (M)
Levered Free Cash Flow -43 (M)

Stock Valuations

PE Ratio -7.67
PEG Ratio -0.2
Price to Book value 8.37
Price to Sales 0
Price to Cash Flow -10.47

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-01-22
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.